A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions

Healthy Subjects

Interventions

DRUG

Placebo

8 placebo tablets matching E2609

DRUG

E2609

E2609 will be administered as 8 tablets

DRUG

Moxifloxacin

Administered as 1 tablet with 7 tablets of placebo matching E2609

Trial Locations (1)

San Antonio

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT02222324 - A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects | Biotech Hunter | Biotech Hunter